Regarding the efficacy and therapeutic sequence of ALK inhibitors among IMT patients, the use of ALECTINIB follows the same rational as in treatment of NSCLC after progression on CRIZOTINIB (10, 21). The gene discussed is ALK; the disease is inflammatory myofibroblastic tumor.